FilingReader Intelligence
Lupin launches glucagon injection in US market
August 11, 2025 at 05:09 AM UTC•By FilingReader AI
Lupin Limited has launched Glucagon for Injection USP, 1mg/vial, packaged in an emergency kit, in the United States. The product is indicated for severe hypoglycemia and as a diagnostic aid.
The estimated annual sale of Glucagon for Injection USP was $122 million, according to IQVIA MAT June 2025 data.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:LUPIN•Bombay Stock Exchange
News Alerts
Get instant email alerts when Lupin publishes news
Free account required • Unsubscribe anytime